The FDA approved Eli Lilly's potent obesity drug tirzepatide, which will be marketed under the name Zepbound. This approval makes it the second drug in its class approved for obesity treatment, after Novo Nordisk's Wegovy. In trials, Zepbound achieved weight loss of up to 21% of body weight, higher than the 15% achieved by Wegovy. Both target the GLP-1 and GIP hormones. Lilly expects Zepbound to be available in US pharmacies after Thanksgiving. It will be priced the same as Mounjaro at over $1,000 per month, around 20% lower than Wegovy. Lilly is doubling its manufacturing capacity to meet demand.